Hydrogen Therapy Helps Rare Heart Disease Patient When Other Treatments Failed

Summary by Hydrogen Studies Editorial Team · Updated

Authors
Journal
In Vivo
Year
DOI
10.21873/invivo.13797
Study Type
Human
Outcome
Positive
Peer Reviewed
Yes
Country
Taiwan
Health Condition
Sjögren's Syndrome
Body System
Cardiovascular

TL;DR

A woman with severe lung and heart complications from a connective tissue disease improved after treatment with molecular hydrogen, suggesting a new potential therapy for this condition.

Key Finding

A patient with severe, treatment-resistant pulmonary arterial hypertension showed clinical symptom stabilization and improved immune cell profiles after receiving molecular hydrogen therapy as an add-on treatment.

Summary

This case report describes a 56-year-old woman with a severe lung and heart condition (pulmonary arterial hypertension related to Sjögren's syndrome) that did not improve with standard medications. When she started taking daily hydrogen capsules in 2023, her symptoms stabilized and blood tests showed changes in immune cells—specifically an increase in regulatory T cells (immune cells that calm inflammation) and a decrease in harmful antibodies. She experienced no side effects.

Practical Takeaway

This is a single case report, not a controlled study, so it provides only early, preliminary evidence that hydrogen therapy may help in this specific severe condition. While the patient's immune markers and symptoms improved, larger and more rigorous studies are needed before hydrogen therapy can be recommended for this disease. Anyone with pulmonary arterial hypertension should discuss any new treatments with their doctor.

Abstract (excerpt)

Background/aim: Connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) is a severe complication characterized by elevated pulmonary artery pressure, which can lead to right heart failure and death, if untreated. Standard treatments often fail to adequately manage symptoms…

Read the full abstract via DOI